Influenza Treatment Guidelines

Introduction to Antiviral Therapy

The American Academy of Pediatrics recommends Oseltamivir as the first-line treatment for influenza, which should be started within 48 hours of symptom onset to reduce the duration of symptoms and the risk of complications 1
Patients must meet certain criteria to be considered for neuraminidase inhibitor treatment, including acute influenza-like illness, fever (>38°C), and symptoms present for no more than two days 2
The Centers for Disease Control and Prevention suggests that antiviral treatment may still be beneficial for patients with severe illness, those with complications, or those with progressive disease, even if symptoms have been present for more than 48 hours 3, 6

Neuraminidase inhibitors, such as Oseltamivir, are effective against both influenza A and B, and are recommended for treatment and prevention 4, 5
The American Academy of Pediatrics recommends the following antiviral medications: Oseltamivir (oral), Zanamivir (inhalation), and Peramivir (intravenous) for patients aged 2 years and older 5

The recommended dosage for Oseltamivir is 75mg twice daily for 5 days for adults, and the dosage for children is based on weight, with a maximum dose of 75mg twice daily for those weighing over 40kg 1, 2, 4, 5
For patients with renal impairment (creatinine clearance <30 mL/min), the dosage should be reduced by half (75mg once daily) 1

Early initiation of antiviral treatment can reduce the risk of influenza-related complications, such as pneumonia, respiratory failure, and death 3, 6
Treatment started within 48 hours of symptom onset is most effective, and can shorten the duration of symptoms by approximately 1 day 3, 6

The Infectious Diseases Society of America recommends that antibiotics should not be used to treat uncomplicated influenza, but may be considered for patients with worsening symptoms or those at high risk for complications 1, 2
For patients with severe influenza-related pneumonia, antibiotics should be started immediately, with a preferred regimen of broad-spectrum beta-lactam antibiotics plus a macrolide antibiotic 1, 2

The Centers for Disease Control and Prevention recommends that the following high-risk groups should be prioritized for antiviral treatment: children under 2 years, adults over 65 years, those with chronic medical conditions, and immunocompromised individuals 2, 3, 6
Pregnant women and postpartum women within 2 weeks of delivery should also be prioritized for antiviral treatment 3, 6

Common adverse effects of Oseltamivir include nausea (12-15%) and vomiting (2.5-14%), which can be improved by taking the medication with food 7
Zanamivir is not recommended for patients with airway disease, such as asthma or chronic obstructive pulmonary disease, due to the risk of severe bronchospasm 5

Antiviral medications can be used for influenza prevention, but should not replace vaccination 8, 9
The recommended prophylactic dosage for Oseltamivir is 75mg once daily for 10 days, and can be used to prevent influenza in household contacts within 48 hours of exposure 4, 5